Back to search

Article

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies

2022-01-23

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Chile was severely affected by COVID19 outbreaks but was also one of the first countries to start a nationwide program to vaccinate against the disease. Furthermore, Chile became one of the fastest countries to inoculate a high percentage of the target population and implemented homologous and heterologous booster schemes in late 2021 to prevent potential immunological waning....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8613847a-ce06-5945-ae26-3d0508ddf859
DOI
10.1101/2022.01.14.22269289
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodiesDOI 10.1101/2022.01.14.22269289
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodiesSemantic proximity
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concernSemantic proximity
Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialSemantic proximity
An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in ChileSemantic proximity
Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster doseSemantic proximity
The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2Semantic proximity
Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 MonthsSemantic proximity
Effect of Vaccine Booster, Vaccine Type, and Hybrid Immunity on Humoral and Cellular Immunity Against SARS-CoV-2 Ancestral Strain and Omicron Variant Sublineages BA.2 and BA.5 Among Older Adults with Comorbidities: An Observational StudySemantic proximity
BRIEF COMMUNICATION: High level of Anti SARS-Co-V2 RBD Antibody one year post booster vaccine hospital workers in Indonesia; Was second booster needed?Semantic proximity
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed AdultsSemantic proximity
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2Semantic proximity
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of ConcernSemantic proximity
Select a neighboring publication to make it the new centre.